ATLAS INTERVERTEBRAL BODY CAGE
Device Facts
| Record ID | K092774 |
|---|---|
| Device Name | ATLAS INTERVERTEBRAL BODY CAGE |
| Applicant | Spinal Edge, LLC |
| Product Code | MAX · Orthopedic |
| Decision Date | Feb 2, 2010 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 888.3080 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
When used as vertebral body replacement, the ATLAS Intervertebral Body Cage is indicated for use in the thoracolumbar spine (T1-L5) to replace a collapsed, damaged or unstable vertebral body due to tumor or trauma. The ATLAS Intervertebral Body Cage is intended to be used with supplemental fixation systems that have been labeled for use in the thoracic and/or lumbar spine (i.e. posterior pedicle screw and rod systems, anterior plate systems, and anterior screw and rod systems) the interior spacer may be packed with bone grafting material. The ATLAS Intervertebral Body Cage has been designed to provide anterior column support even in the absence of fusion for a prolonged period of time. When used as a lumbar intervertebral body fusion device the ATLAS Intervertebral Body Cage is intended for spinal fusion procedures to be used with autogenous bone graft in skeletally mature individuals with degenerative disc disease (DDD) at one or two contiguous spinal levels from L2 to S1. DDD is defined and discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should have six months of non-operative treatment. These DDD patients may have had previous non-fusion spinal surgery at the involved spinal level(s). The ATLAS Intervertebral Body Cage is implanted via an anterior or posterior approach and is combined with supplemental fixation. For either intended use, the ATLAS Intervertebral Body Cage must be used with supplemental internal fixation.
Device Story
ATLAS Intervertebral Body Cage; titanium alloy spacer; fixed heights/footprints; axial hole for bone graft; superior/inferior surface protrusions for endplate gripping/expulsion resistance. Implanted via anterior or posterior approach; requires supplemental internal fixation (pedicle screw/rod or plate systems). Used in clinical settings by surgeons for spinal stabilization/fusion. Provides anterior column support; facilitates bone fusion; stabilizes collapsed/damaged vertebrae. Device extension adds 8-16mm size options.
Clinical Evidence
Bench testing only. Mechanical testing performed on the largest (17mm) cage size per ASTM F2267-04 (load-induced subsidence) and ASTM F2077-03 (spinal implant constructs in a vertebrectomy model). Results demonstrate mechanical equivalence to predicate devices.
Technological Characteristics
Titanium alloy (ASTM F-136); intervertebral body cage with axial graft hole and surface protrusions; fixed heights/footprints; requires supplemental internal fixation; mechanical testing per ASTM F2267-04 and ASTM F2077-03.
Indications for Use
Indicated for skeletally mature patients requiring vertebral body replacement in the thoracolumbar spine (T1-L5) due to tumor or trauma, or spinal fusion for degenerative disc disease (DDD) at one or two contiguous levels (L2-S1) following six months of failed non-operative treatment.
Regulatory Classification
Identification
An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.
Special Controls
*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.